2016

Senegal: The impact of a study on misoprostol use and knowledge among pharmacists

Eva Burke
E. Robinson
Nafissatou Diop
*Population Council*
Kate Reiss
Katharine Footman

*See next page for additional authors*

Follow this and additional works at: [https://knowledgecommons.popcouncil.org/departments_sbsr-rh](https://knowledgecommons.popcouncil.org/departments_sbsr-rh)

Part of the Demography, Population, and Ecology Commons, Family, Life Course, and Society Commons, Gender and Sexuality Commons, International Public Health Commons, Maternal and Child Health Commons, Pharmacy and Pharmaceutical Sciences Commons, Public Health Education and Promotion Commons, and the Women's Health Commons

**How does access to this work benefit you? Let us know!**

**Recommended Citation**

This Case Study is brought to you for free and open access by the Population Council.
Authors
Eva Burke, E. Robinson, Nafissatou Diop, Kate Reiss, Katharine Footman, Maaike Van Min, Barbara Reichwein, and Ian Askew

This case study is available at Knowledge Commons: https://knowledgecommons.popcouncil.org/departments_sbsr-rh/244
**SUMMARY**

The availability of misoprostol is a key part of improving maternal health in low- and middle-income countries. In Senegal, where the drug is not widely available, pharmacies are one of the few places women can access it.

STEP UP conducted a study to understand misoprostol knowledge and provision in these pharmacies. Stakeholder uptake of the results brought about several important achievements:

- Expansion of MSI’s regional programme strategy to include training of both pharmacists and health care providers;
- Provision of information on the legal status and correct regimen of Misoclear during pharmaceutical detailer visits, to improve pharmacists’ knowledge of and confidence to purchase and sell misoprostol;
- A commitment from the Ministry of Health to train pharmacists on misoprostol was secured.
INTRODUCTION

Misoprostol is scarcely available in Senegal, despite being essential for the management of postpartum hemorrhage (PPH) and post-abortion care (PAC) and included on the List of Essential Medicines (EML) of both the World Health Organization (WHO) and the Senegalese Ministry of Health (MoH).

Misoprostol in Senegal can only be obtained via prescription, and is supplied almost exclusively by private sector facilities. It is not procured by the MoH for the public sector, with only 1% of public sector health providers reporting its use in 2013.

THE PROJECT

In 2013, Marie Stopes International (MSI) and the Population Council conducted a study on misoprostol knowledge and distribution practices amongst private pharmacies in Dakar. The study is part of the work undertaken by the "Strengthening Evidence for Programming on Unintended Pregnancy (STEP UP)" research consortium, with funding from DFID.

The aim of the study was to inform strategies to improve misoprostol provision in an effort to reduce maternal mortality, by gaining an understanding of the knowledge, attitudes and practices (KAP) of misoprostol provision amongst 110 private sector pharmacists in Dakar. The study took place in the context of governmental targets to reduce maternal mortality from 392 in 2010/11 to 127 deaths per 100,000 live births by the end of 2015.

KEY STUDY RESULTS

- Only 35% of pharmacists sold misoprostol, of which the majority (70%) reported selling it only for duodenal or gastric ulcers, rather than for gynaecological conditions such as postpartum haemorrhage (PPH) and post abortion care (PAC).
- Less than 5% of pharmacists knew misoprostol could be used for the management of PPH, none reported selling it for this purpose, and none knew the correct dosage.
- Only 13% of pharmacists knew misoprostol was registered for PAC; 3.7% reported selling it for this indication, but only 0.5% of all pharmacists knew the correct dosage.
- 51% of pharmacists reported not being confident providing misoprostol to clients.
- 38% of pharmacists knew that misoprostol can be used to induce abortion.
- Only one respondent reported having sold misoprostol to a client without a prescription;
- 48% of those not selling misoprostol expressed a desire to do so.
- 42% of those not stocking misoprostol stated that the reason was that they did not want to sell abortifacient products.

Fig. 1: Pharmacist reasons for not selling Misoprostol

MAKING AN IMPACT

Influencing policies and programming improvements

This section presents how the evidence from the study was used, and what impact it had on access to misoprostol in Senegal.

Expansion of MSI's programme strategy to include training of health care providers

The low sales of misoprostol for gynecological indications reported by pharmacists were in part due to a lack of prescriptions issued by health care providers, such as doctors, nurse and midwives. As a result of the study, MSI broadened its strategy to include training of public providers, having previously focused on capacity building amongst pharmacists alone to increase access to misoprostol.

MSI Senegal collaborated with the Ministry of Health and Gynuity Health Projects to train 1020 public sector service providers in 35 districts on the uses of misoprostol by January 2015, with plans to train another 1200 by late 2015. This strategy of training health care providers later became part of MSI's regional approach to scaling up access to misoprostol in West Africa.
Improving communication with pharmacists to build confidence to sell misoprostol

Low knowledge of misoprostol registration status and regimen for gynaecological indications limited pharmacists’ confidence in procuring and selling the product. In response, the pharmaceutical detailers responsible for marketing Misoclear (MSI’s branded product) to pharmacists were re-trained on its use and their remit expanded, enabling them to share information on the legal status and correct provision of Misoclear. These topics are now covered during detailing visits with the aim of imparting knowledge and improving confidence to purchase and sell misoprostol.

The impact of this strategy is evidenced by the increase in the number of pharmacists who stock Misoclear from 253 in December 2014 to 415 pharmacists in June 2015.¹

Commitment by the Ministry of Health to train pharmacists on misoprostol

Two dissemination events were held, co-hosted with the Directorate of Reproductive Health and Child Survival (DSRSE). These events provided opportunities for MSI Senegal and the Population Council to highlight the importance of misoprostol and its contribution to reducing maternal mortality in Senegal to stakeholders and the media. At the second dissemination event, the MoH committed to training pharmacists on all essential medicines, including misoprostol. The events were a result of the strong relationship between the study team and the DSRSE.

Who will benefit?

Through these improvements in service access, quality, and political and programmatic support, there is the potential that benefits will be seen at a number of levels:

- **Individuals:** Fewer women may suffer or die of treatable maternal health conditions like PPH and PAC by using misoprostol. Not only will they be able to obtain this lifesaving drug from more locations, but the improved skills of public sector providers and pharmacists may result in better quality services.

- **Communities:** Women play central roles in family and community life. By improving access to misoprostol, preventable deaths and diseases may be avoided, helping to keep communities stable and healthy.

- **National goals:** Senegal’s goal of reducing maternal mortality from 392 in 2010/11 to 127 deaths per 100,000 live births by the end of 2015 is made more attainable by this progress towards making misoprostol more available to women who need it.

¹ - MSI Senegal only has information related to Misoclear and not other brands of misoprostol on the market.

HOW WAS IMPACT ACHIEVED?

**SOME KEY LESSONS LEARNED**

**Strong relationships with policymakers**

The two dissemination events that contributed to the Ministry of Health’s commitment to train pharmacists on misoprostol were the result of the strong relationship between the study team and the DSRSE. Not only did the events enable widespread dissemination of information on misoprostol’s role in reducing maternal mortality, but they were also co-hosted with the DSRSE; this helped to promote the Ministry’s ownership of the study’s recommendations. The director of the DSRSE is also a supporter of improving women’s access to evidence-based family planning and reproductive health services, and his commitment enabled further support and utilization of the study’s findings.

**Support of the Order of Pharmacists**

The involvement of the Order of Pharmacists from project inception was essential for building ties with the pharmacists involved in the study. The Order provided the list of pharmacies in Dakar, and prior to data collection they sent informational letters to the pharmacies to introduce them to the project. This enabled early links with pharmacists, and may have bolstered their engagement with the research team as well as their receptiveness to the more accurate information shared by the re-trained pharmaceutical detailers who market and explain the legal status and uses of Misoclear.
CONCLUSION

By evidencing barriers to misoprostol access and provision, this study raised awareness for a little understood public health issue that continues to contribute to maternal mortality in Senegal.

The MoH’s commitment to training public providers and pharmacists on all products on the essential medicines list is a promising step towards bettering the health of women in Senegal. At the time of writing, the pharmacy training had not yet been brought to fruition.

Further research is needed to investigate the knowledge, attitudes and practices of service providers responsible for prescribing misoprostol, as well as the impact that training such providers will have on use of the product.

MSI Senegal continues to work to build the capacity of healthcare providers in the public sector, while both MSI Senegal and the Population Council remain committed to supporting the MoH to reduce levels of maternal mortality from PPH and PAC.

Suggested citation:

REFERENCES AND SUGGESTED READINGS


